Diaceutics

Diaceutics

DXRX.L
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $45.5M

Market Cap: $202.9MFounded: 2005Employees: 201-500HQ: Belfast, United Kingdom

Overview

Diaceutics' mission is to ensure every patient receives the right therapy at the right time by solving the commercialization challenges of precision medicine. The company has evolved from a consultancy into a data and analytics-driven platform leader, serving over 20 of the world's top pharmaceutical companies and hundreds of therapy programs. Its core strategy revolves around its DXRX platform, which aggregates global lab data and applies AI to generate actionable insights, enabling pharmaceutical clients to optimize testing rates, physician education, and ultimately, therapy adoption.

OncologyRare DiseasesCardiologyNeurologyAutoimmune

Technology Platform

DXRX - The Diagnostic Network®, the world's first diagnostic commercialization platform. It integrates real-world diagnostic data from a global laboratory network and uses AI/ML analytics to power engagement modules like DXRX Signal, Physician Engage, and Expert Exchange.

Funding History

3
Total raised:$45.5M
Series B$15M
IPO$25M
Series A$5.5M

Opportunities

The massive and growing precision medicine market, where significant patient attrition due to diagnostic gaps creates a multi-billion-dollar problem for pharma.
Expansion into new therapeutic areas like cardiology and neurology, and the increasing need for real-world evidence to satisfy regulators and payers, further drive demand for Diaceutics' platform.

Risk Factors

Revenue dependence on a concentrated set of large pharmaceutical clients.
The core business relies on maintaining exclusive laboratory data partnerships, which could be disrupted.
Intensifying competition from larger CROs and data firms, alongside complex global data privacy regulations, pose ongoing challenges.

Competitive Landscape

Competes with large CROs/consultancies (e.g., IQVIA) offering broad services, real-world data firms (e.g., Flatiron, Tempus) focused on clinical outcomes, and specialist diagnostic consultancies. Diaceutics differentiates through its first-mover DXRX platform, proprietary global diagnostic dataset, and unique closed-loop model integrating data, AI insights, and direct physician engagement tools.

Company Timeline

2005Founded

Founded in Belfast, United Kingdom

2018Series A

Series A: $5.5M

2019IPO

IPO — $25.0M

2020Series B

Series B: $15.0M